COST-EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Taheri, S. [1 ]
Motevalli, M. H. [1 ]
Peiravian, F. [1 ]
Yousefi, N. [1 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacoecon & Pharma Management, Tehran, Iran
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN168
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [41] Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
    Chen, Shuling
    Peng, Zhenwei
    Wei, Mengchao
    Liu, Weifeng
    Dai, Zihao
    Wang, Haibo
    Mei, Jie
    Cheong, Mingfong
    Zhang, Hanmei
    Kuang, Ming
    BMC CANCER, 2018, 18
  • [42] Cost-Effectiveness of Sorafenib Versus Selective Internal Radiation Therapy for Patients with Advanced Hepatocellular Carcinoma
    Parikh, Neehar Dilip
    Singal, Amit G.
    Kulik, Laura M.
    Hutton, David
    HEPATOLOGY, 2018, 68 : 532A - 533A
  • [43] Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
    Hou, Yanli
    Wu, Bin
    CANCER COMMUNICATIONS, 2020, 40 (12) : 743 - 745
  • [44] Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses
    Mohammadnezhad, Ghader
    Esmaily, Hadi
    Talebi, Maryam
    Jafari, Matin
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (02) : 625 - 637
  • [45] Cost-Effectiveness Of Image-Based Screening Methods For Hepatocellular Carcinoma In Cirrhotic Patients: A Systematic Review
    Xiong, Zhengping
    Chen, Wendong
    Huang, Fang
    Sherman, Morris
    HEPATOLOGY, 2013, 58 : 392A - 392A
  • [46] COST EFFECTIVENESS OF SORAFENIB VERSUS SBRT FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Chan, A.
    Leung, H.
    VALUE IN HEALTH, 2016, 19 (03) : A152 - A152
  • [47] EFFICACY, EFFECTIVENESS, SAFETY AND COST-EFFECTIVENESS OF THE USE OF SORAFENIB IN DIFFERENTIATED THYROID CANCER. A SYSTEMATIC REVIEW
    Machado, Miranda P.
    Carrasquilla-Sotomayor, M.
    Alvis-Zakzuk, N. J.
    Alvis-Zakzuk, J. S.
    de la Rosa, Gomez F.
    Guzman, Alvis N.
    VALUE IN HEALTH, 2017, 20 (05) : A90 - A90
  • [48] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [49] Safety and Effectiveness of Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
    Prasanthan, Ardra Thottarath
    Raju, Dona
    Vinayakumar, Syamaprasad Thachethukunnil
    Jacob, Mary
    Chandran, Anand
    Vijayan, Meenu
    Keechilatu, Pavithran
    CURRENT CANCER THERAPY REVIEWS, 2022, 18 (02) : 148 - 151
  • [50] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Gong, Hongyu
    Ong, Siew Chin
    Li, Fan
    Weng, Zhiying
    Zhao, Keying
    Jiang, Zhengyou
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
12345